These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 3494504)
1. Effect of anti-B16 melanoma monoclonal antibody on established murine B16 melanoma liver metastases. Eisenthal A; Lafreniere R; Lefor AT; Rosenberg SA Cancer Res; 1987 Jun; 47(11):2771-6. PubMed ID: 3494504 [TBL] [Abstract][Full Text] [Related]
2. Induction of antibody-dependent cellular cytotoxicity in vivo by IFN-alpha and its antitumor efficacy against established B16 melanoma liver metastases when combined with specific anti-B16 monoclonal antibody. Eisenthal A; Cameron RB; Rosenberg SA J Immunol; 1990 Jun; 144(11):4463-71. PubMed ID: 2111349 [TBL] [Abstract][Full Text] [Related]
4. Effect of combined therapy with lymphokine-activated killer cells, interleukin 2 and specific monoclonal antibody on established B16 melanoma lung metastases. Eisenthal A; Cameron RB; Uppenkamp I; Rosenberg SA Cancer Res; 1988 Dec; 48(24 Pt 1):7140-5. PubMed ID: 3263900 [TBL] [Abstract][Full Text] [Related]
5. Biological and antitumor effects of recombinant human macrophage colony-stimulating factor in mice. Bock SN; Cameron RB; Kragel P; Mulé JJ; Rosenberg SA Cancer Res; 1991 May; 51(10):2649-54. PubMed ID: 2021943 [TBL] [Abstract][Full Text] [Related]
6. Role of organ-associated NK cells in decreased formation of experimental metastases in lung and liver. Wiltrout RH; Herberman RB; Zhang SR; Chirigos MA; Ortaldo JR; Green KM; Talmadge JE J Immunol; 1985 Jun; 134(6):4267-75. PubMed ID: 3989307 [TBL] [Abstract][Full Text] [Related]
7. In vivo requirement for asialo GM1 and Thy1 positive leukocytes for antitumor effect of rIL-2 +/- rIFN-gamma. Silagi S; Dutkowski R; Schaefer A Anticancer Res; 1988; 8(6):1265-9. PubMed ID: 2905882 [TBL] [Abstract][Full Text] [Related]
8. Mechanism of antitumor action of pyrimidinones in the treatment of B16 melanoma and P388 leukemia. Li LH; Wallace TL; Richard KA; Tracey DE Cancer Res; 1985 Feb; 45(2):532-8. PubMed ID: 3967227 [TBL] [Abstract][Full Text] [Related]
9. Eradication of melanoma pulmonary metastases by immunotherapy with tumor cells engineered to secrete interleukin-2 or gamma interferon. Abdel-Wahab Z; Dar M; Osanto S; Fong T; Vervaert CE; Hester D; Jolly D; Seigler HF Cancer Gene Ther; 1997; 4(1):33-41. PubMed ID: 9012449 [TBL] [Abstract][Full Text] [Related]
10. Augmentation of the antimetastatic effect of anticoagulant drugs by immunostimulation in mice. Gorelik E Cancer Res; 1987 Feb; 47(3):809-15. PubMed ID: 3802083 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of the growth of human melanoma metastases in nude mice by melanoma-specific murine monoclonal antibody. Abdel-Wahab ZA; Darrow TL; Vervaert CE; Giannopoulou AA; Li W; Seigler HF Surg Oncol; 1992 Apr; 1(2):115-25. PubMed ID: 1341242 [TBL] [Abstract][Full Text] [Related]
12. Systemic induction of cells mediating antibody-dependent cellular cytotoxicity following administration of interleukin 2. Eisenthal A; Rosenberg SA Cancer Res; 1989 Dec; 49(24 Pt 1):6953-9. PubMed ID: 2573425 [TBL] [Abstract][Full Text] [Related]
13. Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases. Cameron RB; McIntosh JK; Rosenberg SA Cancer Res; 1988 Oct; 48(20):5810-7. PubMed ID: 3262413 [TBL] [Abstract][Full Text] [Related]
15. [Role of asialo GM 1 positive cells in the control of metastatic spread of tumor cells in mice]. Shibuya M; Saijo N; Ozaki A; Beppu Y; Shimizu E; Takizawa T; Hoshi A Gan To Kagaku Ryoho; 1983 Aug; 10(8):1781-6. PubMed ID: 6882003 [TBL] [Abstract][Full Text] [Related]
16. Sequential chemoimmunotherapy with cisplatin, interferon-beta and interleukin-2 inhibits the growth of B16-F1 melanoma in syngeneic mice. Kubo H; Matsumoto K; Funahashi M; Takagi H; Kitajima Y; Taniguchi S; Saida T Melanoma Res; 2000 Jun; 10(3):223-9. PubMed ID: 10890375 [TBL] [Abstract][Full Text] [Related]
17. Enhanced suppression of melanoma tumor growth and metastasis by combined therapy with anti-VEGF receptor and anti-TYRP-1/gp75 monoclonal antibodies. Patel D; Bassi R; Hooper AT; Sun H; Huber J; Hicklin DJ; Kang X Anticancer Res; 2008; 28(5A):2679-86. PubMed ID: 19035294 [TBL] [Abstract][Full Text] [Related]
18. Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma. Teicher BA; Ara G; Buxton D; Leonard J; Schaub RG Clin Cancer Res; 1997 Sep; 3(9):1661-7. PubMed ID: 9815857 [TBL] [Abstract][Full Text] [Related]
19. A monoclonal antibody against a human B lymphoblastoid cell line induces tumor regression in mice. Hardy B; Yampolski I; Kovjazin R; Galli M; Novogrodsky A Cancer Res; 1994 Nov; 54(22):5793-6. PubMed ID: 7954401 [TBL] [Abstract][Full Text] [Related]
20. Intratumoral IL-18 gene transfer improves therapeutic efficacy of antibody-targeted superantigen in established murine melanoma. Wang Q; Yu H; Ju DW; He L; Pan JP; Xia DJ; Zhang LH; Cao X Gene Ther; 2001 Apr; 8(7):542-50. PubMed ID: 11319621 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]